Cite

HARVARD Citation

    Padovani, A. et al. (2022). "Real‐world" eligibility for aducanumab depends on clinical setting and patients' journey. Journal of the American Geriatrics Society. 70 (2), pp. 626-628. [Online]. 
  
Back to record